GMA131

 

GMA131

-

 

Endothelin-1/endothelin receptor A (ETa) axis is important in human cardiovascular system, and it also plays a big role in regulating renal function and responses to injury associated with diabetic kidney disease (DKD). GMA131, a humanized monoclonal antibody specifically against ETa, may become the first antibody drug for DKD with excellent efficacy and insignificant adverse effects.

 

GMA131 was approved by the US FDA on Nov 11, 2022 for the clinical study of diabetic kidney disease (DKD).